Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has ... royalty rate. Lilly’s last attempt to develop a non-opioid pain drug was with Pfizer ...

Eli Lilly’s new chief executive David Ricks has made his first acquisition, bringing in biotech CoLucid for $960 million – reacquiring a migraine drug the big pharma sold off 12 years ago.

Alvidrez’s son, also named Steven, said they got the news of Lilly’s arrest two nights ago. The courtroom Friday afternoon was absolutely packed as dozens showed up to support the Alvidrez ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...